Latest Commercialization News

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Elanor Commercial Property Fund reported a solid FY25 with strong income and portfolio stability, while rejecting an unsolicited takeover bid from Lederer Group.

Elanor Commercial Property Fund has met its FY25 earnings guidance with robust leasing activity and a strong occupancy rate, setting a stable foundation for FY26 despite market headwinds.

Elanor Commercial Property Fund reported a $5.4 million statutory loss for FY25 despite a slight increase in Funds from Operations, while navigating a strategic capital raise and an unsolicited takeover offer from the Lederer Group.

Intelligent Monitoring Group Limited (IMG) reported a 44% revenue surge to $174.9 million in FY25, driven by four key acquisitions and organic growth, while investing heavily in AI-powered video monitoring technology.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Estrella Resources and its partner PT Raka Energi Mandiri have agreed to extend key project milestones for their Werumata limestone venture in Timor-Leste, reflecting internal delays but maintaining a positive outlook.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Lake Resources N.L. has updated its Kachi Phase One DFS Addendum, showcasing improved lithium brine grades, enhanced extraction technology, and stronger project economics, positioning the Kachi lithium project closer to development.

Decidr AI Industries has locked in a $3.9 million underwriting agreement with Morgans Corporate Limited to back the exercise of listed options expiring this month, providing crucial funding ahead of its DecidrOS Beta release.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.